• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Merck

Whistleblower: FDA downplayed safety issues at Merck vaccine plant

April 2, 2021 By Brian Buntz Leave a Comment

A former FDA inspector accused the agency of downplaying safety problems at a Merck plant tapped to manufacture Johnson & Johnson’s COVID-19 vaccine. The whistleblower alleged that a 2018 inspection uncovered evidence that employees in the facility in Durham, N.C.engaged in a host of unsanitary practices. A letter to President Biden from the U.S. Office […]

Filed Under: Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Johnson & Johnson, Merck

Merck spinoff Organon to acquire Alydia Health for up to $240M

March 30, 2021 By Sean Whooley Leave a Comment

Merck (NYSE: MRK) announced today that it entered into an agreement for its spinoff Organon to acquire Alydia Health for up to $240 million. Alydia Health develops treatments focusing on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding, according to a news release. The company develops the Jada […]

Filed Under: Business/Financial News, Featured, Gynecological, Mergers & Acquisitions, Women's Health Tagged With: alydiahealth, Merck, Organon

Report: Biden to buy 100M additional doses of J&J COVID-19 vaccine

March 10, 2021 By Sean Whooley

President Joe Biden is reportedly set to announce plans to purchase an additional 100 million doses of Johnson & Johnson’s (NYSE:JNJ) COVID-19 vaccine. An NBC News report said that Biden is set to announce the purchase of the single-dose vaccines on Wednesday, according to two officials from his administration. Get the full story at our sister site, Drug Discovery […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, COVID-19 vaccine, Johnson & Johnson, Merck

Merck moving to Phase 2 study of drug-eluting implant to prevent HIV infection

March 8, 2021 By Sean Whooley

Merck (NYSE:MRK) today announced positive results from a Phase 1 study of its subdermal drug-eluting implant for preventing HIV-1 infection. The investigational implant has the potential for extended administration of islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection, according to a news release. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Pharmaceutical Tagged With: HIV/AIDs, Merck

Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine

March 2, 2021 By Sean Whooley

President Joe Biden is reportedly set to announce a partnership in which Merck (NYSE:MRK) will make Johnson & Johnson’s (NYSE:JNJ) recently approved COVID-19 vaccine. The Washington Post reported that the agreement between the two competitors will boost the supply of the single-dose vaccine from J&J’s Janssen subsidiary, which received FDA emergency use authorization last week. Get the full story at […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, COVID-19 vaccine, COVID-19 vaccines, Johnson & Johnson, Merck

Drug companies agree not to release COVID-19 vaccine until it’s ready

September 8, 2020 By Sean Whooley

Executives from nine different drug companies today announced a pledge to ensure safety with a potential COVID-19 vaccine. The CEOs of AstraZeneca (NYSE:AZN), BioNTech (NSDQ:BNTX), GlaxoSmithKline (NYSE:GSK), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Moderna (NSDQ:MRNA), Novavax (NSDQ:NVAX), Pfizer (NYSE:PFE) and Sanofi (NYSE:SNY), all of whom are developing vaccine candidates, all signed the pledge, which vows to “uphold the integrity of the scientific process” […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: AstraZeneca plc, BioNTech, coronavirus, COVID-19, Donald Trump, GlaxoSmithKline plc, Johnson and Johnson, Merck, Moderna, Novavax Inc., Pfizer, Sanofi

The most innovative pharmaceutical agents of 2020

August 3, 2020 By Danielle Kirsh

The Galien Foundation recently announced nominees for most innovative pharmaceutical agents for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical, pharmaceutical drugs and medical technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien process, […]

Filed Under: Cardiovascular, Featured, Neurological, Oncology, Pharmaceutical Tagged With: AbbVie, Adlon Therapeutics, Advanced Accelerator Applications, Astellas Pharma, Bayer, Eli Lilly & Co., Galien Foundation, Genentech, Greenwich Biosciences, GW Pharmaceuticals, Janssen Biotech, Johnson & Johnson, Karyopharm Therapeutics, Medicines Development for Global Health, Merck, Novartis, Pfizer, Population Council, Purdue Pharma, Roche Group, Servier Pharmaceuticals, SIGA Technologies, Sobi, TB Alliance, Theravance Biopharma

MedTech 100 roundup: Another rebound as markets continue to fluctuate

June 22, 2020 By Sean Whooley

Medtech stocks rebounded from a significant dip earlier in June last week, continuing to highlight the topsy-turvy nature of the markets during the COVID-19 pandemic. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 85.00 points at the end of last week (June 19). That total represents […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: 3m, coronavirus, COVID-19, Dept. of Health & Human Services (HHS), foxconn, MedTech 100 Index, Medtronic, Merck, Merit Medical Systems, Owens and Minor, Proteus Digital Health, Stryker, Themis

Merck acquires Themis to speed COVID-19 vaccine development

June 19, 2020 By Sean Whooley

Merck (NYSE:MRK) announced today that it completed the acquisition of vaccine and immune-modulation therapy developer Themis for an undisclosed amount. In connection with the acquisition, the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, while Merck gained merger control from the Austrian Federal Competition Authority, […]

Filed Under: Business/Financial News, Clinical Trials, Mergers & Acquisitions, Pharmaceutical Tagged With: coronavirus, COVID-19, Merck, Themis

Merck eyes tiny patches as a vaccine delivery method

May 28, 2020 By Chris Newmarker

Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today. The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceutical Tagged With: Harro Höfliger, Merck, Vaxxas

RefleXion, Merck team up on late-stage cancer study

May 28, 2020 By Sean Whooley

RefleXion announced today that it entered into a clinical collaboration with Merck to evaluate Merck’s (NYSE:MRK) Keytruda anti-PD-1 therapy in clinical trials. Hayward, Calif.-based therapeutic oncology company RefleXion is joining forces with Merck to evaluate Keytruda’s safety and efficacy in combination with RefleXion’s biology-guided radiotherapy (BgRT) in multiple late-stage cancers, including non-small cell lung cancer, in […]

Filed Under: Business/Financial News, Clinical Trials, Featured, Imaging, Oncology, Radiosurgery/Radiation therapy Tagged With: Merck, RefleXion Medical

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS